Ardea Biosciences, Inc

Oscotec Inc.

Genosco

Hong Woo Kim

Zhi Hong

Jean-Luc Girardet

Jong Sung Koh

Jaekyoo Lee

Ho-Juhn Song

Hee Kyu Lee

Yung-Hyo Koh

Stephanie Shaw

Jang-Sik Choi

Sunhwa Chang

Youngsam Kim

Sun-Hee Lim

Jung-ho Kim

Jean-Michel Andre Vernier

In Y Lee

Jung-Ho Kim

Shunqi Yan

Martha Alicia De La Rosa

Esmir Gunic

Se Ryung Kim

Se-Won Kim

Marion Hitchcock

Stanley Lang

Yung Hyo Koh

Stanley Valeant Research & Development Lang

Jean Luc Girardet

Se Won Kim

In Yong Lee

Stanley A Lang

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I). 

Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors

This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N'-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.

Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

Kinase inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.

Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV

A series of S-triazolyl &#x3b1;-mercaptoacetanilides having general structure (1) are provided, where Q is COH, CONR, SOH, or SONR. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections. 

S-triazolyl &#x3b1;-mercapto acetanilides as inhibitors of HIV reverse transcriptase

Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV

Growing community of inventors

San Diego, CA, United States of America

Hong Woo Kim